CN108136003A - 抗pd-1和抗m-csf抗体在癌症治疗中的联合应用 - Google Patents

抗pd-1和抗m-csf抗体在癌症治疗中的联合应用 Download PDF

Info

Publication number: CN108136003A
Authority: CN; China
Prior art keywords: ser; thr; val; leu; lys
Prior art date: 2015-07-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN201680044470.5A

Other languages

English (en)

Chinese (zh)

Inventor

M-L·夫杰尔斯考格

J·卡梅伦

Z·曹

D·希伯勒塔

K·马西萨克

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-29

Filing date

2016-07-27

Publication date

2018-06-08

2016-07-27 Application filed by Novartis AG filed Critical Novartis AG

2018-06-08 Publication of CN108136003A publication Critical patent/CN108136003A/zh

Status Pending legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Cell Biology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Pregnancy & Childbirth (AREA)
Hematology (AREA)
Oncology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CN201680044470.5A 2015-07-29 2016-07-27 抗pd-1和抗m-csf抗体在癌症治疗中的联合应用 Pending CN108136003A (zh)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201562198384P	2015-07-29	2015-07-29
US62/198,384		2015-07-29
US201662352637P	2016-06-21	2016-06-21
US62/352,637		2016-06-21
PCT/IB2016/054487 WO2017017623A1 (en)	2015-07-29	2016-07-27	Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer

Publications (1)

Publication Number	Publication Date
CN108136003A true CN108136003A (zh)	2018-06-08

Family

ID=56682136

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201680044470.5A Pending CN108136003A (zh)	2015-07-29	2016-07-27	抗pd-1和抗m-csf抗体在癌症治疗中的联合应用

Country Status (18)

Country	Link
US (1)	US11001628B2 (2)
EP (1)	EP3328425B1 (2)
JP (1)	JP6840127B2 (2)
KR (1)	KR20180034426A (2)
CN (1)	CN108136003A (2)
AU (1)	AU2016300208B2 (2)
BR (1)	BR112018000212A2 (2)
CA (1)	CA2991857A1 (2)
CL (1)	CL2018000222A1 (2)
IL (1)	IL256691A (2)
JO (1)	JO3784B1 (2)
MX (1)	MX2018001263A (2)
PH (1)	PH12018500174A1 (2)
RU (1)	RU2742494C2 (2)
SA (1)	SA518390834B1 (2)
TN (1)	TN2017000554A1 (2)
TW (1)	TWI735456B (2)
WO (1)	WO2017017623A1 (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2021227782A1 (zh) *	2020-05-15	2021-11-18	三生国健药业（上海）股份有限公司	一种抗pd-1和pd-l1的四价双特异性抗体
CN114173818A (zh) *	2019-06-13	2022-03-11	西托姆克斯治疗公司	可活化抗pdl1抗体和抗ctla-4抗体在用于治疗癌症的新辅助联合疗法中的用途
CN114173815A (zh) *	2019-06-13	2022-03-11	西托姆克斯治疗公司	可活化抗pdl1抗体和抗ctla-4抗体在用于治疗癌症的联合疗法中的用途

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015048312A1 (en)	2013-09-26	2015-04-02	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
PE20170255A1 (es)	2014-01-24	2017-03-22	Dana Farber Cancer Inst Inc	Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
HUE045065T2 (hu)	2014-01-31	2019-12-30	Novartis Ag	TIM-3 antitest molekulák és felhasználásaik
KR102442436B1 (ko)	2014-03-14	2022-09-15	노파르티스 아게	Lag-3에 대한 항체 분자 및 그의 용도
KR20170060042A (ko)	2014-09-13	2017-05-31	노파르티스 아게	Alk 억제제의 조합 요법
MX383464B (es)	2015-07-13	2025-03-14	Cytomx Therapeutics Inc	Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
HRP20211058T8 (hr)	2015-07-29	2021-11-26	Novartis Ag	Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
IL300122A (en)	2015-11-18	2023-03-01	Merck Sharp ַ& Dohme Llc	Substances that bind to PD1 and/or LAG3
AR112603A1 (es) *	2017-07-10	2019-11-20	Lilly Co Eli	Anticuerpos biespecíficos inhibidores de punto de control
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
US12174192B2 (en)	2018-07-12	2024-12-24	Corvus Pharmaceuticals, Inc.	Methods for detecting and treating cancers having adenosine pathway activation
US12116635B2 (en)	2018-07-12	2024-10-15	Corvus Pharmaceuticals, Inc.	Methods for detecting and treating cancers having adenosine pathway activation
WO2020044252A1 (en) *	2018-08-31	2020-03-05	Novartis Ag	Dosage regimes for anti-m-csf antibodies and uses thereof
MX2021009562A (es) *	2019-02-12	2021-09-08	Novartis Ag	Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
WO2020239558A1 (en)	2019-05-24	2020-12-03	Pfizer Inc.	Combination therapies using cdk inhibitors
US20220168293A1 (en)	2020-12-02	2022-06-02	Pfizer Inc.	Time to resolution of axitinib-related adverse events
TW202327595A (zh)	2021-10-05	2023-07-16	美商輝瑞大藥廠	用於治療癌症之氮雜內醯胺化合物的組合
WO2023079428A1 (en)	2021-11-03	2023-05-11	Pfizer Inc.	Combination therapies using tlr7/8 agonist

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015026634A1 (en) *	2013-08-20	2015-02-26	Merck Sharp & Dohme Corp.	Treating cancer with a combination of a pd-1 antagonist and dinaciclib
WO2015042246A1 (en) *	2013-09-20	2015-03-26	Bristol-Myers Squibb Company	Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101899114A (zh)	2002-12-23	2010-12-01	惠氏公司	抗pd-1抗体及其用途
SI2311873T1 (sl) *	2004-01-07	2018-12-31	Novartis Vaccines And Diagnostics, Inc.	M-CSF-specifična monoklonska protitelesa in njihova uporaba
DK2439273T3 (da)	2005-05-09	2019-06-03	Ono Pharmaceutical Co	Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
RU2450018C2 (ru) *	2006-08-23	2012-05-10	Йеда Рисерч Энд Диверлопмент Ко. Лтд	Конъюгаты rgd-пептидов и фотосенсибилизаторов порфирина или (бактерио)хлорофилла и их применение
AU2007296259A1 (en) *	2006-09-15	2008-03-20	Janssen Pharmaceutica Nv	Combinations of class-I specific histone deacetylase inhibitors with proteasome inhibitors
CN101970499B (zh)	2008-02-11	2014-12-31	治疗科技公司	用于肿瘤治疗的单克隆抗体
EP2262837A4 (en)	2008-03-12	2011-04-06	Merck Sharp & Dohme	PD-1 BINDING PROTEINS
JP2012500855A (ja)	2008-08-25	2012-01-12	アンプリミューン、インコーポレーテッド	Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
AU2009288730B2 (en)	2008-08-25	2013-06-20	Amplimmune, Inc.	Compositions of PD-1 antagonists and methods of use
WO2011066342A2 (en)	2009-11-24	2011-06-03	Amplimmune, Inc.	Simultaneous inhibition of pd-l1/pd-l2
AR097306A1 (es)	2013-08-20	2016-03-02	Merck Sharp & Dohme	Modulación de la inmunidad tumoral
AR097584A1 (es)	2013-09-12	2016-03-23	Hoffmann La Roche	Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
PE20170255A1 (es) *	2014-01-24	2017-03-22	Dana Farber Cancer Inst Inc	Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas

2016
- 2016-07-27 EP EP16750495.0A patent/EP3328425B1/en active Active
- 2016-07-27 KR KR1020187002247A patent/KR20180034426A/ko not_active Ceased
- 2016-07-27 AU AU2016300208A patent/AU2016300208B2/en not_active Ceased
- 2016-07-27 CN CN201680044470.5A patent/CN108136003A/zh active Pending
- 2016-07-27 RU RU2018106876A patent/RU2742494C2/ru active
- 2016-07-27 TN TNP/2017/000554A patent/TN2017000554A1/en unknown
- 2016-07-27 CA CA2991857A patent/CA2991857A1/en not_active Abandoned
- 2016-07-27 WO PCT/IB2016/054487 patent/WO2017017623A1/en not_active Ceased
- 2016-07-27 US US15/879,064 patent/US11001628B2/en not_active Expired - Fee Related
- 2016-07-27 MX MX2018001263A patent/MX2018001263A/es unknown
- 2016-07-27 BR BR112018000212A patent/BR112018000212A2/pt not_active IP Right Cessation
- 2016-07-27 JP JP2018504105A patent/JP6840127B2/ja not_active Expired - Fee Related
- 2016-07-28 JO JOP/2016/0162A patent/JO3784B1/ar active
- 2016-07-29 TW TW105124178A patent/TWI735456B/zh not_active IP Right Cessation
2018
- 2018-01-01 IL IL256691A patent/IL256691A/en unknown
- 2018-01-23 PH PH12018500174A patent/PH12018500174A1/en unknown
- 2018-01-26 CL CL2018000222A patent/CL2018000222A1/es unknown
- 2018-01-29 SA SA518390834A patent/SA518390834B1/ar unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015026634A1 (en) *	2013-08-20	2015-02-26	Merck Sharp & Dohme Corp.	Treating cancer with a combination of a pd-1 antagonist and dinaciclib
WO2015042246A1 (en) *	2013-09-20	2015-03-26	Bristol-Myers Squibb Company	Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YU ZHU等: "CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models", 《CANCER RESEARCH》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN114173818A (zh) *	2019-06-13	2022-03-11	西托姆克斯治疗公司	可活化抗pdl1抗体和抗ctla-4抗体在用于治疗癌症的新辅助联合疗法中的用途
CN114173815A (zh) *	2019-06-13	2022-03-11	西托姆克斯治疗公司	可活化抗pdl1抗体和抗ctla-4抗体在用于治疗癌症的联合疗法中的用途
WO2021227782A1 (zh) *	2020-05-15	2021-11-18	三生国健药业（上海）股份有限公司	一种抗pd-1和pd-l1的四价双特异性抗体
US12269886B2 (en)	2020-05-15	2025-04-08	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Tetravalent bispecific antibody against PD-1 and PD-L1

Also Published As

Publication number	Publication date
JP6840127B2 (ja)	2021-03-10
CA2991857A1 (en)	2017-02-02
SA518390834B1 (ar)	2021-03-02
KR20180034426A (ko)	2018-04-04
TW201718011A (zh)	2017-06-01
WO2017017623A1 (en)	2017-02-02
RU2018106876A (ru)	2019-08-28
IL256691A (en)	2018-03-29
US11001628B2 (en)	2021-05-11
HK1247848A1 (zh)	2018-10-05
JO3784B1 (ar)	2021-01-31
CL2018000222A1 (es)	2018-07-13
AU2016300208B2 (en)	2019-08-08
US20180222973A1 (en)	2018-08-09
MX2018001263A (es)	2018-04-13
JP2018525367A (ja)	2018-09-06
RU2018106876A3 (2)	2020-07-17
EP3328425B1 (en)	2021-08-25
RU2742494C2 (ru)	2021-02-08
PH12018500174A1 (en)	2018-07-30
AU2016300208A1 (en)	2018-02-01
TWI735456B (zh)	2021-08-11
EP3328425A1 (en)	2018-06-06
BR112018000212A2 (pt)	2018-09-04
TN2017000554A1 (en)	2019-04-12

Legal Events

Date	Code	Title	Description
2018-06-08	PB01	Publication
2018-06-08	PB01	Publication
2018-08-24	SE01	Entry into force of request for substantive examination
2018-08-24	SE01	Entry into force of request for substantive examination
2022-06-03	AD01	Patent right deemed abandoned	Effective date of abandoning: 20220603
2022-06-03	AD01	Patent right deemed abandoned

Publication	Publication Date	Title
CN108136003A (zh)	2018-06-08	抗pd-1和抗m-csf抗体在癌症治疗中的联合应用
CN107530428B (zh)	2022-05-13	Icos的抗体
CN110392694B (zh)	2023-08-04	针对pd-1的抗体及其用途
CN109071666B (zh)	2022-06-28	人脊髓灰质炎病毒受体(pvr)特异性抗体
JP6920194B2 (ja)	2021-08-18	抗ｔｉｇｉｔ抗体
DK3097121T3 (en)	2019-04-15	ANTIBODY MOLECULES AGAINST PD-1 AND APPLICATIONS THEREOF
CN109715667A (zh)	2019-05-03	抗-gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子及其用途
CN109790223A (zh)	2019-05-21	用于治疗癌症的抗siglec-7抗体
AU2016298823A1 (en)	2018-02-08	Combination of PD-1 antagonist with an EGFR inhibitor
CN108738324A (zh)	2018-11-02	抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
KR20140113912A (ko)	2014-09-25	Her3에 특이적인 결합 분자 및 이의 용도
JP7843824B2 (ja)	2026-04-10	抗体および使用方法
KR20200092976A (ko)	2020-08-04	항-cd137 항체 및 이의 용도
JP7430137B2 (ja)	2024-02-09	抗体および使用方法
WO2024102980A1 (en)	2024-05-16	Anti-alpha5 integrin antibodies and uses thereof
WO2022166987A1 (zh)	2022-08-11	结合lag-3的抗体及其用途
TW202523694A (zh)	2025-06-16	抗muc16抗體及其用途
WO2025230866A1 (en)	2025-11-06	Anti-alpha5 integrin antibodies and uses thereof
CN121620534A (zh)	2026-03-06	抗tigit抗体及其用途
EA053156B1 (ru)	2026-04-24	Антитела к sirp-альфа
HK1247848B (en)	2021-12-17	Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
HK1248127B (en)	2023-01-27	Antibodies to icos